100% anonymous · Verified U.S. prescribers only
(no name, NPI, or practice ever shown)| NCT | Phase | Status | Sponsor | Primary Completion |
|---|---|---|---|---|
| NCT07720271 | Phase 3 | RECRUITING | Novo Nordisk A/S | Jun 27, 2028 |
| NCT07797335 | Phase 3 | RECRUITING | Novo Nordisk A/S | Jul 31, 2028 |
| NCT07668414 |
| Phase 3 |
| RECRUITING |
| Novo Nordisk A/S |
| Oct 10, 2028 |
Share your pre-launch perspective on zenagamtide and help peers make informed prescribing decisions.
Your 45-second perspective helps thousands of colleagues.
Your real-world insights guide colleagues
Your identity stays private — only specialty/region shown
Compare your perspective to specialty peers